Corresponding author: Jundong GU, E-mail: jundonggu@yahoo.cn Abstract Background and objective Although evidence for a significant survival benefit of chest radiotherapy has been proven, no conclusion could be drawn regarding the optimal timing of chest radiation. The aim of this study is to explore whether the timing of chest radiation may influence the survival of the patients with limited-stage small-cell lung cancer (LS-SCLC) by performing a literature-based meta-analysis. Methods By searching Medline, CENTRAL (the Cochrane central register of controlled trials), CBM, and CNKI, et al, we collected both domestic and overseas published documents about randomized trials comparing different timing chest radiotherapy in patients with LS-SCLC. Early chest radiation was regarded as beginning within 30 days after the start of chemotherapy. Random or fixed effect models were applied to conduct meta-analysis on the trials. The combined odds ratio (OR) and the 95% confidence interval (CI) were calculated to estimate the mortality in 2 or 3 years and toxicity of the two treatments. The statistical heterogeneity was determined by cochran's Chi-square test (Q test). The Begg' test was used to determine the publication bias. Results Six trials that included a total of 1 189 patients were analyzed in the meta-analysis 587 patients were in the early radiation group and 602 patients were in the late radiation group.
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[2] 15% [3] 2 -4 [4] meta [5] [ 6, 7] www.lungca.org In this study, 151 patients (Eastern Cooperative Oncology Group [ECOG] score 0-2) were randomized in an unblinded fashion to either standard oncologic care or early palliative care, integrated as part of the multidisciplinary treatment for patients with newly diagnosed advanced NSCLC. The intervention consisted of meetings with a palliative care team within 3 weeks of enrolment and at least monthly thereafter in the outpatient setting until death. Patients on the control arm were able to receive palliative care services if requested by the patient or physician. The primary outcome of the study was the change in quality of life from baseline to 12 weeks measured by the Functional Assessment Cancer Therapy (FACT) Lung Scale. Secondary outcomes included depression, use of health services including anti-cancer therapy, medications, hospice, hospital admission, emergency department visits, and overall survival. Patients were classified as having received 'aggressive end-of-life care' if they met any of the following criteria: chemotherapy within 14 days before death, no hospice care, or admission to hospice 3 days or less before death. All analyses were intention to treat. Results confirmed the expected outcome: early palliative care improved quality of life scores and decreased depressive symptoms (16% vs. 38%). Fewer patients in the palliative care group received 'aggressive end-of-life care' (33% vs. 54%). Most interestingly, the median overall survival was longer among patients receiving earlier palliative care (11.6 months vs. 8.9 months, p=0.02). Proposed hypotheses for improved overall survival include indirect benefits of decreased depression, decreased hospitalizations due to improved symptom control or, possibly, decreased toxicity from minimizing futile 'aggressive end-of-life care'. This study suggests that early palliative care can improve quality of life and symptoms, while having a positive impact on overall survival. The survival difference is similar in magnitude to that seen in practice-changing treatment trials for metastatic lung cancer. Strengths of the study include the randomized study design and use of multiple relevant outcomes including survival. A limitation of this study is that it is based in a single institution and should be validated at other sites to establish generalizability. In addition, the unblinded design and lack of attention control may have influenced outcomes, particularly selfreport assessments. However, these results should promote consideration of a shift in paradigm to incorporate palliative care early, as part of standard oncologic management, which may improve outcomes for many older patients. Please click here for the free full text to the article.
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